Explore more publications!
Potomac Health News
Submit Press Release

Potomac Health News: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Potomac Health News.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on November 7, 2025

New White Paper Highlights the Value of Price Transparency Data for Healthcare Investors
November 7, 2025

New White Paper Highlights the Value of Price Transparency Data for Healthcare Investors

Indeterminate EIN Presswire
Project UNITY Takes the Stage at APHA 2025: Empowering Youth to Lead the Future of Public Health
November 7, 2025

Project UNITY Takes the Stage at APHA 2025: Empowering Youth to Lead the Future of Public Health

Indeterminate EIN Presswire
All Smiles Dental Studio Launches Full Dental Implant Services and In-House Membership Plan to Support the Encinitas Community
November 7, 2025

All Smiles Dental Studio Launches Full Dental Implant Services and In-House Membership Plan to Support the Encinitas Community

Indeterminate GlobeNewswire
Protext Mobility, Inc. (OTC: TXTM) Announces Launch Phase of Its Next-Generation Investor Relations Suite and Corporate Website Modernization — Ushering in a New Era of Transparency, Innovation, and Shareholder Confidence
November 7, 2025

Protext Mobility, Inc. (OTC: TXTM) Announces Launch Phase of Its Next-Generation Investor Relations Suite and Corporate Website Modernization — Ushering in a New Era of Transparency, Innovation, and Shareholder Confidence

Indeterminate GlobeNewswire
PetVivo Sets Fiscal Second Quarter 2026 Conference Call for Friday, November 14, 2025 at 5:00 p.m. ET
November 7, 2025

PetVivo Sets Fiscal Second Quarter 2026 Conference Call for Friday, November 14, 2025 at 5:00 p.m. ET

Indeterminate GlobeNewswire
Neurocept Unveiled: Exploring the Science Behind This Neurocept Brain Support Supplement Transforms Cognitive Health and Memory Enhancement
November 7, 2025

Neurocept Unveiled: Exploring the Science Behind This Neurocept Brain Support Supplement Transforms Cognitive Health and Memory Enhancement

Indeterminate GlobeNewswire
Global Patient Monitoring Market to Reach $55.8 Billion by End of 2030
November 7, 2025

Global Patient Monitoring Market to Reach $55.8 Billion by End of 2030

Indeterminate GlobeNewswire
OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines
November 7, 2025

OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines

Indeterminate GlobeNewswire
Présentation poster sur OSE-Cytomask®, une technologie innovante de « Cis-Démasquage » des cytokines visant à augmenter l’indice thérapeutique des immunocytokines
November 7, 2025

Présentation poster sur OSE-Cytomask®, une technologie innovante de « Cis-Démasquage » des cytokines visant à augmenter l’indice thérapeutique des immunocytokines

Indeterminate GlobeNewswire
Chemed Corporation Declares Quarterly Dividend of 60 Cents
November 7, 2025

Chemed Corporation Declares Quarterly Dividend of 60 Cents

Indeterminate GlobeNewswire
ADARx Pharmaceuticals Announces Positive Interim Phase 1 Clinical Data for its Novel siRNA Targeting Complement Factor B (CFB)
November 7, 2025

ADARx Pharmaceuticals Announces Positive Interim Phase 1 Clinical Data for its Novel siRNA Targeting Complement Factor B (CFB)

Indeterminate GlobeNewswire
CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 7, 2025

CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Indeterminate GlobeNewswire
Upcoming Knock Out Opioid Abuse Day Webinar to Focus on the Biology of Addiction
November 7, 2025

Upcoming Knock Out Opioid Abuse Day Webinar to Focus on the Biology of Addiction

Indeterminate GlobeNewswire
Easy Environmental Solutions Begins Trading Under New Ticker Symbol “EZES”
November 7, 2025

Easy Environmental Solutions Begins Trading Under New Ticker Symbol “EZES”

Indeterminate GlobeNewswire
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
November 7, 2025

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Indeterminate GlobeNewswire
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
November 7, 2025

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Indeterminate GlobeNewswire
Nouscom Presents New Positive Phase 1/2b data of NOUS-209 at SITC 2025, Supporting Plans to Initiate Registration-Enabling Study for Cancer Interception in Lynch Syndrome Carriers
November 7, 2025

Nouscom Presents New Positive Phase 1/2b data of NOUS-209 at SITC 2025, Supporting Plans to Initiate Registration-Enabling Study for Cancer Interception in Lynch Syndrome Carriers

Indeterminate GlobeNewswire
Tizona Therapeutics Presents Clinical Translational Evidence of Dual Innate and Adaptive Immune Activation with TTX-080, a First-in-Class HLA-G Antagonist, in Patients with Advanced Solid Tumors at SITC 2025
November 7, 2025

Tizona Therapeutics Presents Clinical Translational Evidence of Dual Innate and Adaptive Immune Activation with TTX-080, a First-in-Class HLA-G Antagonist, in Patients with Advanced Solid Tumors at SITC 2025

Indeterminate GlobeNewswire
T-knife Therapeutics Presents Preclinical Data on PRAME-Targeted TK-6302 Highlighting its Potential as a Promising, Category-leading Therapy at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 7, 2025

T-knife Therapeutics Presents Preclinical Data on PRAME-Targeted TK-6302 Highlighting its Potential as a Promising, Category-leading Therapy at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Indeterminate GlobeNewswire
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
November 7, 2025

BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions